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Abstract: Methamphetamine is a potent addictive stimulant drug that activates certain systems in the brain. It is a member 
of the amphetamine family, but the effects of methamphetamine are much more potent, longer lasting, and more harmful 
to the central nervous system. Repeated administration of methamphetamine induces behavioral sensitization, which is 
considered to be related to compulsive drug-seeking behavior. Although the mechanism responsible for methampheta-
mine-induced behavioral sensitization remains unclear, it is believed that the mesolimbic dopaminergic system in the  
central nervous system plays a critical role in the development of behavioral sensitization. Our previous studies indicate 
that the involvement of the μ-opioid receptor system underlies the development of methamphetamine-induced behavioral 
sensitization. Understanding the mechanisms of behavioral sensitization that are regulated by the μ-opioid receptor system 
would be helpful in developing therapeutic programs against methamphetamine addiction. This review briefly discusses 
the neural circuitry and cellular mechanisms that are known to play a central role in methamphetamine-induced behavioral 
sensitization and outlines the role of the μ-opioid receptor system in the development of methamphetamine-induced   
sensitization. 
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BACKGROUND 
  Methamphetamine is a central nervous system stimulant 
drug that is similar in structure to amphetamine but has a 
higher potential for abuse, resulting in behavioral changes 
including sensitization, tolerance, and dependence [1]. It has 
been suggested that sensitization contributes to both initia-
tion and maintenance of drug addiction [2]. Drug addiction is 
mediated by multiple brain regions and neurotransmitter 
systems. The mesolimbic dopaminergic system in the central 
nerve system is thought to play a critical role in the devel-
opment of addictive behavior [3, 4] and is strongly modu-
lated by other neurotransmitter systems, including the opioi-
dergic [5], glutamatergic [6], and -aminobutyric acid 
(GABAergic) systems [7]. Many studies have shown that the 
dopaminergic and opioidergic systems interact in the 
mesolimbic brain areas. For example, microinjection of [D-
Ala2, N-Me-Phe4-Gly5-ol]-enkephalin (DAMGO; a μ-
opioid receptor agonist) caused an increase in the ventral 
striatal DA and DA-metabolite concentrations in rats [8]. 
Pharmacological evidence also indicates that acute admini-
stration of morphine increases the level of extracellular do-
pamine in the nucleus accumbens and striatum of mice [9, 
10]. Lesions of dopaminergic neurons [11, 12] or neuroleptic 
blockade [13] of dopamine receptors attenuated opiatere-
ward, as measured by intracranial electrical self-
stimulation,conditioned place preference (CPP), and intrave-  
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nous self-administration. Moreover, our previous studies 
have shown that blockade of the μ-opioid receptor caused 
reduced development of methamphetamine-induced sensiti-
zation [14-16] and that these results were related to the 
changes in the levels of dopamine and its metabolites [17], as 
well as to the binding of dopamine receptors [18]. Therefore, 
understanding the role the μ-opioid receptor plays in dopa-
minergic neurotransmission underlying methamphetamine-
induced behavioral sensitization would facilitate the discov-
ery of a new therapy program against addiction to psy-
chostimulants. This review briefly outlines the investigation 
on the role of the μ-opioid receptor in the development of 
methamphetamine-induced sensitization. 
Development of an Animal Model for Methampheta-
mine-Induced Behavioral Sensitization 
  Repeated administration of methamphetamine has been 
known to produce a progressively enhanced and persistent 
behavioral response in rodents, a phenomenon called “be-
havioral sensitization” [14, 19]. Behavioral sensitization has 
been used as an animal model for studying the development 
of craving in addicts and psychosis that arises from repeated 
exposure to psychostimulants [19, 20]. Previous studies have 
indicated that once sensitization has developed, a challenge 
dose (low dose) of methamphetamine resulted in behavioral 
hyperactivity, characterized by increase in locomotor activity 
and stereotyped behaviors in mice [14, 21]. For example, 
mice injected with 2.5 mg/kg of methamphetamine once a 
day for 7 consecutive days showed behavioral hyperactivity 
after challenge with 0.3125 mg/kg of methamphetamine on 
day 11 [14]. For the initiation of behavioral sensitization to 
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i.p. injection of methamphetamine or saline (control) for 5 to 
7 consecutive days. For the evaluation of the expression of 
behavioral sensitization, the sensitized mice received one 
injection of methamphetamine (the same dose or lower as for 
initiation) or saline challenge on day 11 (with 4 abstinent 
days) or day 21 (with 14 abstinent days). Although the 
mechanism responsible for methamphetamine-induced be-
havioral sensitization remains unclear, it is believed that the 
mesolimbic dopaminergic system in the central nervous sys-
tem plays a critical role in the development of behavioral 
sensitization [4, 22, 23]. It has been reported that a challenge 
dose of methamphetamine (2 mg/kg) markedly increased 
dopamine turnover (lower dopamine and higher 3, 4-
dihydroxyphenylacetic acid (DOPAC) levels, higher ratios of 
DOPAC over dopamine) in the striatum and nucleus accum-
bens of the sensitized animals on day 15 of withdrawal from 
daily treatment with the drug, 6 mg/kg, for 14 days [3]. 
These findings demonstrate that behavioral sensitization in-
duced by methamphetamine is accompanied by increased 
central dopaminergic transmission [3, 4, 23]. 
Role of μ-Opioid Receptor in Methamphetamine-Induced 
Sensitization 
  Topographic overlaps between the μ-opioid receptor and 
dopamine neurons were found in the central nervous system, 
suggesting that there are interactions between these two sys-
tems [24, 25]. Mu opioid receptor activation has been shown 
to play a role in psychostimulant-induced gene expression 
and behavior. For example, pretreatment with the μ-opioid 
receptor antagonist clocinnamox blocked methamphetamine-
induced increases in zif268 messenger RNA expression in 
the dorsal striatum of the rat [26]. Intrastriatal administration 
of morphine given with a low dose of amphetamine that did 
not induce stereotypy resulted in a level of stereotypic be-
havior usually seen with a high dose of amphetamine [27]. 
Our previous studies found that naltrexone, a long-lasting 
universal opioid receptor antagonist, could attenuate the in-
duction and expression of methamphetamine-induced behav-
ioral sensitization in NIH Swiss mice [14, 15]. These results 
show that the expressions of behavioral sensitization were 
attenuated by pretreatment with 10 or 20 mg/kg of naltrex-
one either during the induction period or before 
methamphetamine challenge when they were tested on days 
11 and 21 [14]. In addition, radioligand binding revealed that 
the maximal binding of the μ-opioid receptor, not the 
binding of delta- and kappa-opioid receptors, was down-
regulated on day 8 after 7 daily consecutive administrations 
of methamphetamine. After cessation of drug treatment, the 
maximal binding of the μ-opioid receptor gradually and 
time-dependently returned to normal level on day 11 and up-
regulated on day 21. These findings indicate enhanced re-
sponsiveness and elevated constitutive activity of the μ-
opioid receptor in NIH Swiss mice [15]. Recent evidence 
also demonstrated that the μ-opioid receptor agonist mor-
phine increased methamphetamine-induced reinforcing be-
havior and its association with dopamine release in the stria-
tum of mice [28]. In the study, mice were i.p. injected with 
0.75 mg/kg methamphetamine and 5 mg/kg morphine alone 
or in combination to examine the effects of acute (i.e. once), 
repeated (i.e. once daily for five consecutive days), or chal-
lenge administration (i.e. injection of drugs again after 7-day 
abstinence period) on behaviors including CPP, locomotor 
activity, and stereotyped behavior, as well as on the levels of 
dopamine and its metabolites. The results show that the 
combined administration of methamphetamine and morphine 
resulted in a greater CPP value than treatment with either 
methamphetamine or morphine alone. Treatment with meth-
amphetamine resulted in a progressive increase in ambula-
tory distance, suggesting the development of locomotor sen-
sitization in response to methamphetamine challenge; but 
there were no significant changes in ambulatory distance for 
the group of mice injected with morphine during the course 
of acute, repeated, or challenge administration [28]. Neither 
the single nor combined regimens of drugs had effects on 
stereotyped behavior during five consecutive days of re-
peated administration [28]. In addition, the results revealed 
that challenge with the combination of methamphetamine 
and morphine significantly increased striatal dopamine levels 
compared with challenge with methamphetamine and mor-
phine alone. Challenge with methamphetamine led to a pro-
gressive and time-dependent decrease in striatal levels of 
DOPAC and homovanillic acid (HVA). Neither challenge 
with morphine nor methamphetamine plus morphine pro-
duced significant differences in the DOPAC and HVA levels 
as compared with saline controls [28]. These findings pro-
vide insight into the behavioral and neurochemical basis re-
sponsible for the combined abuse liability of methampheta-
mine and morphine. 
Alternations of Neurochemical Change in Metham-
phetamine-Induced Sensitization in Wild-Type and   
μ-Opioid Receptor Knockout Mice 
  Mu-opioid receptor knockout mice have also shown less 
behavioral sensitization than wild-type mice after repeated 
administration of methamphetamine [16]. The effects of be-
haviors and biochemical factors after blockade or lack of the 
μ-opioid receptor in methamphetamine sensitization are 
summarized in Table 1. Mu-opioid receptor knockout mice 
injected with 0.625 mg/kg of methamphetamine once a day 
for 7 consecutive days showed less behavioral hyperactivity 
as compared with that of the wild-type mice after challenge 
with 0.625 mg/kg of methamphetamine on day 11 and day 
21 [16]. In addition, the levels of dopamine metabolites, 
DOPAC and HVA, were decreased in the striatum of the 
wild-type mice — but not in the μ-opioid receptor knockout 
mice — after 7 consecutive days of treatment followed by 4 
days of drug abstinence (on day 11), as measured by in vivo 
microdialysis [17]. These findings suggest that the μ-opioid 
receptor plays a modulatory role in methamphetamine-
induced behavioral sensitization that is related to dopamine 
metabolism in the mouse striatum. In autoradiographic study, 
our data showed that there was a decreased binding in the D1 
but not the D2 dopamine receptor in the striatum and nucleus 
accumbens of μ-opioid receptor knockout mice, but not wild-
type mice, after repeated administration of methampheta-
mine [18]. It seems that downregulation of the D1 dopamine 
receptor is the main factor behind attenuation of behavioral 
sensitization in μ-opioid receptor knockout mice following 
administration of methamphetamine. However, another set 
of experiments showed that the antagonistic effect of halop-
eridol (a potent D2 dopamine receptor antagonist with a 
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phetamine-induced stereotyped sensitization was more po-
tent in μ-opioid receptor knockout mice than in the wild-type 
controls [16]. These results reveal that the function of D2 
dopamine receptor may turn to be more predominant in μ-
opioid receptor knockout mice as compared with that of 
wild-type controls. 
  Earlier studies have reported that both selective D1 and 
D2 dopamine receptor antagonists not only reversed meth-
amphetamine-induced motor effects at each injection but 
also prevented the development of behavioral sensitization 
induced by repeated methamphetamine administration [22, 
29]. This means that both D1 and D2 dopamine receptor 
systems are involved in the development of behavioral sensi-
tization to methamphetamine [22, 29]. The D1 and D2 do-
pamine receptors have opposing actions on the activity of 
adenylyl cyclase in dopaminergic neurons of the striatum 
and nucleus accumbens. Activation of the D2 dopamine re-
ceptor inhibited adenylyl cyclase activity [30], whereas acti-
vation of the D1 dopamine receptor increased adenylyl cy-
clase activity [31]. These actions resulted in a decrease in the 
level of cAMP and protein kinase A signal, which caused a 
decrease in the phosphorylation of DARPP-32 (dopamine- 
and cAMP-regulated phosphoprotein of Mr 32 kDa)-
dependent signaling pathway [32, 33]. Moreover, through 
the cAMP/PKA, activation of D2 dopamine receptor inacti-
vated phosphorylation of DARPP-32 through increasing cal-
cium levels in the striatum and nucleus accumbens [32]. This 
means that activation of the D2 dopamine receptor can inac-
tivate phosphorylation of DARPP-32 through cAMP/PKA or 
Ca
2+/calcineurin. It has also been reported that phosphoryla-
tion of DARPP-32 may be involved in acute administration 
of cocaine or amphetamine that leads to an increase in loco-
motor activity [34]. These responses were severely attenu-
ated in DARPP-32-deficient mice [34, 35]. These data reveal 
that phosphorylation of DARPP-32 may play an important 
role in the mechanism of behavioral sensitization induced by 
psychostimulants such as methamphetamine in animals. 
SUMMARY 
  The findings summarily indicate that the μ-opioid recep-
tor plays an important role in modulating the development of 
methamphetamine-induced behavioral sensitization through 
dopaminergic neurotransmission. Understanding the regula-
tory mechanism of the μ-opioid receptor on cellular signal-
ing pathways and nuclear gene expression of dopaminergic 
system during the development of methamphetamine-
induced behavioral sensitization would help us to develop 
therapeutic programs against drug addiction. Thus, further 
studies are necessary. 
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